Last reviewed · How we verify
NCT04210778: CRCI
Combined Model of Online Remote Interventions for Cancer-Related Cognitive Impairment
NA trial testing Cognitive orientation to daily occupational performance (CO-OP) in Cognitive Decline in 90 participants. Completed in 30 August 2022.
30 September 2021
Quick facts
| Lead sponsor | Hadassah Medical Organization |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 26 February 2018 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 August 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Cognitive orientation to daily occupational performance (CO-OP)
- Computerized Cognitive Training (BrainHQ, posit science)
Conditions studied
- Cognitive Decline — all drugs for Cognitive Decline →
- Cancer — all drugs for Cancer →
Sponsor
Hadassah Medical Organization — full company profile →
Who can join
18 and older, any sex, with Cognitive Decline or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer survival rates have increased dramatically in recent years. However, many survivors report cognitive decline following treatment, which significantly impairs their quality of life. Online cognitive training programs have shown promise in improving cognitive functions in cancer survivors, but most studies report limited impact of training on everyday function. A complementary treatment approach is functional treatment delivered by occupational therapists, which directly targets daily function. Combining the two approaches has the potential to overcome the limitations of both approaches, enabling improved cognitive functions and transfer to daily function. Remotely-administrated interventions further make treatment accessible and cost-effective. The current study is aimed at testing the efficacy of a novel, combined, remotely-delivered treatment approach: Cognitive Retraining and Functional Treatment(CRAFT), using a Randomized Controlled Trial (RCT) design. 90 cancer survivors will be randomly assigned to receive 15 weeks of either the combined treatment, computerized training only, or treatment-as-usual. Outcomes will be assessed at completion, and following 3 months of no contact, to test immediate and enduring effects of treatment. Baseline predictors for treatment response will be further assessed. Positive results in the proposed study could potentially change the therapeutic landscape for rehabilitation of cancer-related cognitive decline, which currently impair the lives of millions worldwide.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cognitive Retraining and Functional Treatment (CRAFT) for adults with cancer related cognitive impairment: a preliminary efficacy study.
Maeir T, Makranz C, Peretz T, Odem E, et al · · 2023 · cited 16× · PMID 36746805 · DOI 10.1007/s00520-023-07611-y -
Cognitive retraining and functional treatment (CRAFT) for adults with cancer related cognitive impairment: A randomized controlled trial
Maeir T, Makranz C, Peretz T, Odem E, et al · · 2023 · DOI 10.21203/rs.3.rs-2045064/v1
Verify or expand the search:
- PubMed search for NCT04210778
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Decline
Currently open trials in the same condition.
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT07394504 — Effects of Turning Based Dual Task Training on Balance and Mild Cognitive Impairment in Diabetic Peripheral Neuropathy · NA · recruiting
- NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
- NCT07151365 — Plant-based Diets and Healthy Aging · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Other Hadassah Medical Organization trials
Trials by the same sponsor.
- NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
- NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
- NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
- NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04210778 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
- Last refreshed: 14 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04210778.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing